

16 March 2022

Subject: Treatment of Triple-Negative breast cancer with systemic anti-cancer therapies

Please find response below relating to all Breast patients treated between Dec 21 and Feb 22.

The data relates to all breast patients as we are not able to distinguish the triple negative patients from our data

Question :

I'm hoping that you will be able to help me with a Freedom of Information request that I have for the treatment of Breast Cancer.

I am researching the treatment of Triple-Negative (ER negative, PR negative and HER2 negative) breast cancer. Could you please tell me how many patients you have treated for Triple Negative breast cancer in the last 3 months with the following systemic anti-cancer therapies:

- a) Anthracycline (eg doxorubicin) as single agent
- b) Atezolizumab + nab-paclitaxel or paclitaxel
- c) Capecitabine as a single agent = **21**
- d) Eribulin as a single agent or in combination
- e) PARP inhibitor (eg Olaparib)
- f) Pembrolizumab + chemotherapy
- g) Platinum (eg carboplatin, cisplatin) as a single agent = **<5**
- h) Taxane (eg docetaxel, paclitaxel, nab-paclitaxel) as a single agent = **30**
- i) Taxane + Anthracycline based combinations
- j) Vinorelbine as a single agent = **<5**
- k) Other active systemic anti-cancer therapy

Abemaciclib & Fulvestrant = **5**

Abemaciclib = **<5**

AC = **<5**

D-Phesgo = **6**

EC-D & Herceptin = **<5**

EC-D = **10**

EC-D Phesgo = **11**

EC-PC = **9**

16 March 2022

Enhertu	=	<5
FEC 100	=	<5
FEC 50	=	<5
FEC-D	=	19
FEC – Weekly Paclitaxel	=	<5
Fulvestrant	=	18
Goserelin	=	<5
Herceptin	=	12
Kadcyla	=	5
Palbociclib & Fulvestrant	=	<5
Palbociclib	=	40
Pegylated Liposomal Doxorubicin	=	<5
Ribociclib & Fulvestrant	=	<5
Ribociclib	=	9
Zoledronic Acid	=	7